Traditional first-line treatments like corticosteroids and IVIG have shown good initial response rates, with IVIG helping over 80% of newly diagnosed patients and corticosteroids helping 60-80% of patients increase their platelet levels. Newer treatments like fostamatinib (Tavalisse) work differently by preventing platelet destruction rather than just boosting production. This represents an innovative approach to managing ITP symptoms.

Additionally, new therapies in clinical trials like mezagitamab are being studied as potential treatment options, with results expected by late 2024. While comparing treatment effectiveness, it's important to note that each person may respond differently to various treatments. It's recommended to discuss specific treatment options and their potential benefits with your hematologist to determine the best approach for your situation.